SpaceX & Eli Lilly and Company

SpaceX: SpaceX confidentially filed for an initial public offering, which sent space stocks higher.

Eli Lilly and Company: Eli Lilly and Company rose after the United States — Food and Drug Administration approved its new weight loss pill, Foundayo.

SpaceX: SpaceX>>>'s anticipated market debut and IPO plans are a significant event for high-growth technology stocks, raising concerns about potential overexuberance.

Eli Lilly and Company: Eli Lilly and Company>>> advanced after positive trial results for its next-generation obesity drug, retatrutide, which showed benefits beyond weight loss.

SpaceX: Fell below IPO price; aborted Starship test flight; stock down 4.5% in one session.

Eli Lilly and Company: Eli Lilly's stock jumped after a committee of the European Medicines Agency recommended one of its medicines for approval, boosting its market performance.

SpaceX: SpaceX successfully completed the largest IPO in history, raising $75 billion and achieving a market valuation of over $2 trillion, which will fund its ambitious projects in space and AI. Its shares soared on debut, making it one of the most valuable companies globally.

Eli Lilly and Company: Eli Lilly and Company is mentioned as one of the companies that SpaceX's valuation will surpass, emphasizing the magnitude of SpaceX's market entry.

SpaceX: SpaceX's record-setting IPO was expected to dominate, but biotech IPOs have outperformed, indirectly affecting market attention.

Eli Lilly and Company: Eli Lilly has a strategic collaboration with Scribe, which may benefit from Scribe's successful IPO and pipeline progress.

SpaceX: SpaceX shares fell on AI spending concerns, unrelated to the Hormuz deal. It is a minor market mover in this context.

Eli Lilly and Company: Eli Lilly and Company raised its forecast, boosting healthcare stocks. It is not connected to the event.